Sio Capital Management
Sio Capital Management reported 51 stocks worth $470M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AVR (8.6%), GMED (7.6%) and GSK (6.9%). Compared with Q2 2026, the fund opened new positions in MRK, REPL and BMRN, added to GMED, GSK and ICLR, trimmed AVR, SNY and ALLO and sold out of COR, TYRA and WAY.
Latest filing: what Sio Capital Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() AVR Anteris Technologies Global | $40.2M | 8.6% | 5.2M | −367K (−7%) | 8 of 8 | |
| 2 | ![]() GMED Globus Med Inc | $35.7M | 7.6% | 476K | +174K (+58%) | 4 of 8 | |
| 3 | ![]() GSK Gsk PLC ADR F | $32.3M | 6.9% | 671K | +234K (+54%) | 4 of 8 | |
| 4 | ![]() ICLR Icon PLC | $24M | 5.1% | 141K | +53K (+60%) | 6 of 8 | |
| 5 | ![]() SENS Senseonics Hldgs Inc | $23.3M | 5.0% | 2.3M | +698K (+44%) | 4 of 8 | |
| 6 | ![]() MRK Merck & Co Inc | $21.1M | 4.5% | 145K | New position | 4 of 8 | |
| 7 | ![]() IDYA Ideaya Biosciences Inc | $19.2M | 4.1% | 500K | +20K (+4%) | 7 of 8 | |
| 8 | ![]() SNY Sanofi | $14.7M | 3.1% | 356K | −8,018 (−2%) | 7 of 8 | |
| 9 | ![]() ALLO Allogene Therapeutics Inc | $14.6M | 3.1% | 9.1M | −4.2M (−32%) | 2 of 8 | |
| 10 | ![]() MMS Maximus Inc | $14.3M | 3.0% | 268K | −447K (−62%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() COR Cencora Inc | $49.1M | 174K |
![]() TYRA Tyra Biosciences Inc | $22.2M | 695K |
![]() WAY Waystar Hldg Corp | $19M | 926K |
![]() ORKA Oruka Therapeutics Inc | $16.9M | 177K |
CROSS CTRY HEALTHCARE IN | $14.5M | 1.1M |
🔒 Free account: see all 18.
Options
valued at the underlying sharesReported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Sio Capital Management 13F FAQ
What does Sio Capital Management own?
Sio Capital Management reported 51 stocks worth $470M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AVR (8.6%), GMED (7.6%) and GSK (6.9%). The table above lists every position in the filing (the top 10 without an account).
What did Sio Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 12 new positions, 20 added to, 12 trimmed and 18 sold out. New positions include MRK, REPL and BMRN. It sold all of COR, TYRA and WAY.
When will Sio Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Sio Capital Management's portfolio worth?
The Q3 2026 filing reports $470M in US stocks ($529M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.
























